Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rein Therapeutics, Inc.ALRN · Entity 7071 | SVP & Chief Financial Officer | April 15, 2019 | April 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rein Therapeutics, Inc.
Report date April 15, 2019 · Filed April 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-04-14 | Direct | 150,000 |
Reported balance
After 2019-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-15 · Grant · Acquired 150,000 · Balance 150,000 F1: This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2019 Filed Apr 17, 2019 22:44 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-19-010818 · doc4.xml · derivative · entry 1 Dougherty Donald · CIK 0001709592 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:31 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 3,000 | $5.40 | $16,200.00 |
DisclosureSEC source: 0000899243-18-016218 · doc4.xml · nonDerivative · entry 1 Dougherty Donald · CIK 0001709592 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.39 to $5.40 per share. The reporting person undertakes to provide Aileron Therapeutics, Inc., any security holder of Aileron Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:54 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 2,000 | $5.24 | $10,480.00 |
DisclosureSEC source: 0000899243-18-014929 · doc4.xml · nonDerivative · entry 1 Dougherty Donald · CIK 0001709592 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 22:34 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 60,331 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019219 · doc4.xml · derivative · entry 1 Dougherty Donald · CIK 0001709592 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,331 Underlying: Common Stock · 60,331 shares Expires 2027-07-24 F1 · derivative.exercise_date: This option was granted on July 25, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from July 25, 2017. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 17:32 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 140,887 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017605 · doc4.xml · derivative · entry 1 Dougherty Donald · CIK 0001709592 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,887 Underlying: Common Stock · 140,887 shares Expires 2027-06-28 F1 · derivative.exercise_date: These options were granted on June 28, 2017 and vest as to 25% of the shares on June 8, 2018 and vest thereafter as to 2.0833% of the shares in equal monthly installments through June 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.